Pulmonary Cell News 7.42 October 25, 2018 | |
| |
TOP STORYResearchers confirmed that the activation of LIN28B could promote the proliferation and metastasis of lung adenocarcinoma cells and could influence cell cycle, DNA damage repair, and genome instability. They further revealed a let-7-independent Cis-regulator of LIN28B: LIN28B-AS1. [Oncogene] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Lung fibroblasts from smokers and COPD patients displayed in long-term culture a senescent phenotype, characterized by a reduced replicative capacity, an increased senescence and inflammatory profile. [Aging Cell] Full Article Scientists demonstrated that both Euro 4 and Euro 5 carbon particles, deprived of polycyclic aromatic hydrocarbons possibly adsorbed on the soot surface, were able to significantly affect cell viability, inducing autophagy, apoptosis and necrosis; stimulate the release of the pro-inflammatory cytokine IL-18; elicit protein citrullination and peptidyl arginine deiminase activity in normal human bronchial epithelial cells. [Cell Death Dis] Full Article Investigators demonstrated that contact between epithelial cells and conidia led to the inhibition of conidia germination. They demonstrated that this fungistatic process was not associated with the release of any soluble components nor internalization by the epithelial cells. [Sci Rep] Full Article Berberine promoted nuclear factor-erythroid 2-related factor 2 (Nrf2) nuclear translocation and phosphorylation in vitro. After lipopolysaccharide stimulation, this effect was further enhanced, whereas inflammatory factor release and reactive oxygen species generation were significantly decreased. [Phytother Res] Abstract LUNG CANCERTargeting G9a by siRNA-mediated knockdown or by a selective G9a inhibitor UNC0638 significantly inhibited tumor growth, and dramatically suppressed Wnt signaling pathway in vitro and in vivo. The authors showed that treatment with UNC0638 restored the expression of APC2 in these cells through promoter demethylation. [Mol Cancer] Full Article The effects of water-soluble erlotinib were similar to those of conventional erlotinib in terms of inhibiting the proliferation of epidermal growth factor receptor (EGFR)-mutant lung cancer cells and suppressing EGFR signaling. [Mol Oncol] Abstract | Full Article Withaferin A inhibits Epithelial to Mesenchymal Transition in Non-Small Cell Lung Cancer Cells Scientists demonstrated that withaferin A (WFA) displayed time- and concentration-dependent cytotoxicity on A549 and H1299 NSCLC cells. They observed that pretreatment of cells with WFA inhibited cell adhesion, migration, and invasion of A549 and H1299 cells. [Sci Rep] Full Article Gefitinib-resistant A549 CD133+ cells possessed important cancer stemness characteristics, including the abilities to undergo metastasis, angiogenesis, self-renewal, and to express stemness genes and epithelial-mesenchymal transition markers. However, those characteristics were abolished by knocking down Prx II expression. [Cancer Gene Ther] Full Article TdIF1: A Putative Oncogene in NSCLC Tumor Progression Researchers established that TdT-interacting factor 1 (TdIF1) was highly expressed in human NSCLC cell lines compared to a normal lung cell line. shRNA-mediated gene silencing of TdIF1 resulted in the suppression of proliferation and anchorage-independent colony formation of the A549 adenocarcinoma cell line. [Signal Transduct Target Ther] Full Article Subscribe to one of our other 19 science newsletters such as Cancer Stem Cell News & Human Immunology News. | |
| |
REVIEWSNanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer The authors report and analyze the recent progress made to address combination therapy using nanoparticles and anticancer drugs. Nanotechnology has provided the convenient tools for combination therapy. However, for clinical translation, we need continued improvements in the field of nanotechnology. [Int J Mol Sci] Full Article Erdosteine: Drug Exhibiting Polypharmacy for the Treatment of Respiratory Diseases Erdosteine is one of the most used mucoactive agents for the treatment of several respiratory diseases where the overlap of bacterial infection is frequent. Investigators review the literature available on both clinical and in vitro studies that have investigated the effect of erdosteine on the effect of antibiotics when used as combined therapy. [Pulm Pharmacol Ther] Abstract Visit our reviews page to see a complete list of reviews in the pulmonary cell research field. | |
| |
SCIENCE NEWSNovartis announced Phase II preliminary results of the GEOMETRY mono-1 clinical trial of investigational MET inhibitor capmatinib in 94 adult patients with advanced NSCLC harboring MET exon-14 skipping mutations. [Press release from Novartis AG discussing research presented at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich] Press Release Incyte announced Phase II preliminary results of the GEOMETRY mono-1 clinical trial of investigational MET inhibitor capmatinib in 94 adult patients with advanced NSCLC harboring MET exon-14 skipping mutations. [Press release from Incyte Corporation discussing research presented at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich] Press Release | |
| |
INDUSTRY NEWSCollPlant and United Therapeutics Corporation announced that they have entered into a license, development and commercialization agreement for 3D bioprinted lung transplants. [United Therapeutics Corporation] Press Release FDA Approves Asthma Indication for Dupixent® (Dupilumab) Regeneron Pharmaceuticals, Inc. and Sanofi announced the FDA has approved Dupixent® as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. [Regeneron Pharmaceuticals, Inc.] Press Release Genentech, announced positive results from the Phase III IMpower130 study of Tecentriq® plus chemotherapy for the initial treatment of people with previously untreated metastatic NSCLC. [Genentech, Inc.] Press Release Roche announced results from the Phase III ALESIA study, showing that Alecensa® met its primary endpoint of investigator-assessed progression-free survival. [F. Hoffmann-La Roche Ltd] Press Release Forbius announced that the first patient has been dosed in a Phase IIa trial evaluating the efficacy and safety of AVID 100 in patients with squamous NSCLC whose tumors overexpress epidermal growth factor receptor (EGFR). [Forbius] Press Release Santhera Announces Start of Phase Ib/IIa Trial with POL6014 in Patients with Cystic Fibrosis Santhera Pharmaceuticals announced the start of a Phase Ib/IIa multiple ascending dose trial with POL6014 in patients with cystic fibrosis. [Santhera Pharmaceuticals] Press Release East River BioSolutions Awarded NIH SBIR Phase I Grant The award will support further development of a fibrotic lung-specific cell culture substrate that will allow scientists to build more physiologically relevant in vitro models of idiopathic pulmonary fibrosis [East River BioSolutions] Press Release | |
| |
POLICY NEWSNew Head of Indian Research Giant to Tackle Funding Issues and Red Tape One of India’s largest and oldest research and development organizations has a new leader. Shekhar Mande, a structural biologist best known for his work on proteins, starts this month as director-general of the Council of Scientific and Industrial Research. [Nature News] Editorial Hard Brexit Could Cripple UK Science, Say Nobel Prizewinners A coalition of Nobel laureates has said a hard Brexit could cripple UK science, in a letter to Theresa May and the European commission president, Jean-Claude Juncker. The letter, signed by 29 Nobel prizewinners and six Fields medalists, says the UK “must now strive to ensure that as little harm as possible is done to research”. [The Guardian] Editorial
| |
EVENTSNEW Gordon Research Conference: Modeling and Targeting Mucociliary Function in Health and Disease: Genes to Cells to Interaction Networks and Tissues Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Chair – Cancer Metabolomics Non-Clinical (Imperial College of London) Postdoctoral Position – Lung Cancer Biology (UT Southwestern Medical Center) Postdoctoral Research Scientist – Modeling Infection in Human Lung Organoids (Columbia University) Postdoctoral Research Fellow – Respiratory Epithelial Cell Biology (STEMCELL Technologies Inc.) Postdoctoral Position – Human Lung Organoid Research (Columbia University Medical Center) Research Associate – Lung Cancer (University of Cambridge) Postdoctoral Fellow – Vascular and/or Lung Biology (Yale University) Postdoctoral Fellow – Sepsis and Pulmonary Injury Research (University of Maryland) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pulmonary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|